2 common drugs may offer short-term improvements in long-COVID-related fatigue
Two widely available drugs show *limited* promise for long-COVID fatigue—raising cautious hope for millions.
📍 Where it landed
Initial studies found that two commonly used drugs—antihistamines and another unspecified medication—showed only modest, short-term benefits in reducing fatigue for some long-COVID patients. Follow-up reports described the results as underwhelming, with no major breakthroughs or widespread treatment recommendations emerging.
Coverage on the topic has since quieted without further updates on clinical adoption or long-term efficacy.
Epilogue added 43d ago, after coverage quieted.
Where it stands
A new study published by University College London (UCL) finds that **antihistamines** and **low-dose naltrexone** may provide *short-term* relief for fatigue in long-COVID patients. The trial, described as ‘landmark’ by *The Pharmaceutical Journal*, reports modest improvements but emphasizes the need for further research to confirm efficacy and safety. Coverage from *News-Medical* and *CIDRAP* highlights the drugs’ accessibility, while *MedPage Today* frames the results as underwhelming compared to expectations.
The findings stem from a UCL-led trial involving long-COVID patients, with results published across medical and health news outlets. *The Pharmaceutical Journal* and *CIDRAP* focus on the potential of repurposing existing medications, while *MedPage Today* critiques the lack of significant breakthroughs. No specific patient numbers or long-term data are provided, and experts cited in reports urge caution against overinterpretation. Next steps include larger trials to validate the results and assess durability of effects.
Coverage does not yet specify whether regulatory approval or clinical guidelines will follow, but the study may accelerate discussions on fatigue management in long-COVID care. Monitoring will focus on whether these drugs become part of standard treatment protocols—or if alternative therapies emerge.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 43d ago.
The reporting (5)
- Antihistamines show modest benefits for long Covid fatigue treatment News-Medical · 46d ago
- Common Drugs Basically Flunk for Long COVID Fatigue MedPage Today · 46d ago
- Health news round-up: 'landmark' long COVID trial results and are contraceptives linked to brain tumours? The Pharmaceutical Journal · 46d ago
- Commonly used drugs show small benefit for long Covid fatigue UCL | University College London · 46d ago
- 2 common drugs may offer short-term improvements in long-COVID-related fatigue CIDRAP · 46d ago
Answered
Which drugs showed potential benefits?
Antihistamines and low-dose naltrexone, both commonly prescribed for other conditions.
Are the improvements described as significant?
Coverage describes benefits as *modest* or *short-term*, with *MedPage Today* noting they ‘basically flunk’ for long COVID fatigue.
Will these drugs be available immediately for long-COVID patients?
No—coverage emphasizes the need for further trials before any clinical use or regulatory approval.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
Can long COVID be prevented? Two drugs finally show promise
New research identifies two drugs with potential to prevent long COVID, even as brain scan studies pinpoint damage to dopamine neurons.
Researchers link Long COVID to another virus
Emerging research links Long COVID to another virus, as studies continue to explore the condition's causes, treatments, and patient experiences.